Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

• المؤلفون الرئيسيون: S. Pianko, S. Zeuzem, W. L. Chuang, G. R. Foster, S. K. Sarin, R. Flisiak, C. M. Lee, P. Andreone, T. Piratvisuth, S. Shah, A. Sood, J. George, M. Gould, P. Komolmit, S. Thongsawat, T. Tanwandee, J. Rasenack, Y. Li, M. Pang, Y. Yin, G. Feutren, I. M. Jacobson
• التنسيق: دورية
• منشور في: 2018
• الموضوعات: Immunology and Microbiology; Medicine
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84864665171&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/51724
• المؤسسة: Chiang Mai University

Albinterferon alfa-2b (albIFN) is a fusion protein of recombinant human albumin/recombinant interferon (IFN)-α-2b, with â200-h half-life. Safety/efficacy of albIFN q4wk was evaluated in 391 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 2/3. Patients were randomized 3:4:4:4 t...